Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2017/08/009564
CTRI/2017/08/009564
Not yet recruiting
未知

The benefit of EXtending oral antiCOAgulant treatment after acute Cerebral Vein Thrombosis (EX-COA -CVT) - EXCOA-CVT

niversity of Lisbon0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: null- patients with cerebral venous sinus thrombosis,within month of event

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: null- patients with cerebral venous sinus thrombosis,within month of event
Sponsor
niversity of Lisbon
Status
Not yet recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
niversity of Lisbon

Eligibility Criteria

Inclusion Criteria

  • •1\.Patients with acute symptomatic and radiologically confirmed CVT ï?
  • •2\.Age 18 years OR above at entry ï?
  • •3\.CVT must have been diagnosed in less than 1 month before inclusion ï?
  • •4\.The patient must be clinically stable and able to stop parenteral anticoagulation in order to initiate oral anticoagulation ï?  ï?¡
  • •5\.Written informed consent

Exclusion Criteria

  • •1\.Systemic life\-threatening or major bleeding while on anticoagulants during the acute phase of CVT or during the 6 months prior to randomisation (intracranial bleeding due to inclusion CVT is not an exclusion criteria) ï?  ï?¡
  • •2\.General contraindications for anticoagulant therapy ï?
  • •3\.Need for prolonged treatment with antiplatelet drugs, non\-steroidal anti\-inflammatory drugs or other drugs/diseases that interferes significantly with anticoagulant therapy or with INR ï?  ï?¡
  • •4\.Life expectancy less than 2 years due to a pre\-existing condition (including any malignancy) ï?
  • •5\.Child bearing potential without adequate contraceptive measures, pregnancy or breast feeding ï?
  • •6\.Known allergy to study medications ï?
  • •7\.Other conditions judged by the investigator to be an absolute indication for prolonged oral anticoagulation
  • •such as recurrent CVT, VTE after CVT or first CVT with antiphospholipid syndrome or known severe
  • •thrombophilia (antithrombin, protein C or protein S deficiency, homozygous factor V Leiden or prothrombin G20210A mutation or combined abnormalities)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Effects of treatment with oral anticoagulant associated with antibiotic therapy in Covid-19Covid-19B04.820.578.500.540.150
RBR-7nzwkpgniversidade do Sul de Santa Catarina
Recruiting
Not Applicable
The safety and efficacy of direct oral anticoagulants in patients with atrial fibrillation (AF)
JPRN-UMIN000030673Tokyo Medical and Dental University1,000
Completed
Not Applicable
Prescription of Direct Oral Anticoagulant Affects Activated Clotting Time During Percutaneous Coronary Intervention and Bleeding Events
JPRN-UMIN000047650Tokyo women medical university246
Completed
Not Applicable
Improving the safety and efficacy of anticoagulation therapyTopic: BloodSubtopic: Blood (all Subtopics)Disease: Non-malignant haematologyHaematological DisordersAnticoagulation
ISRCTN64826232ewcastle upon Tyne Hospitals NHS Foundation Trust (UK)180
Active, not recruiting
Phase 1
Improving the safety and efficacy of anticoagulation therapy for thromboembolic disease through vitamin K - Improving stability of anticoagulation through vitamin KPatients will be recruited who are receiving long term warfarin therapy for the treatment or prevention of venous or arterial thrombosis or embolism
EUCTR2008-006238-87-GBewcastle upon Tyne Hospitals NHS Foundation Trust180